Literature DB >> 9696826

Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium.

A Scaria1, J A St George, C Jiang, J M Kaplan, S C Wadsworth, R J Gregory.   

Abstract

Replication-defective adenovirus (Ad) vectors have been used for gene transfer to the respiratory epithelium of experimental animals and individuals with cystic fibrosis. Studies from several laboratories have suggested that administration of first-generation Ad vectors results only in transient gene expression in the lung, due at least in part to destruction of vector-transduced cells by host cellular immune responses directed against viral proteins and/or immunogenic transgene products. We have constructed new Ad2-based, E1-deleted vectors encoding a weakly immunogenic transgene, the human cystic fibrosis transmembrane conductance regulator (hCFTR) under the control of the cytomegalovirus enhancer-promoter. These vectors contain wild-type E2 and E4 regions. These new Ad/CFTR vectors were instilled into the lungs of immunocompetent C57BL/6, BALB/c, and C3H mice. In vitro cytotoxic T lymphocyte (CTL) analysis indicated the presence of Ad-specific CTLs in treated mice. However, we were not able to demonstrate a CTL response specific for hCFTR. Reverse transcriptase PCR analysis demonstrated that hCFTR mRNA expression continued in all three strains of mice for at least 70 days, the last time point analyzed. The E3 region did not play a significant role in persistence of the Ad/CFTR vectors in the mouse lung. Functional hCFTR expression was also observed in the nasal epithelia of CF mutant mice. These results suggest that long-term expression of hCFTR is possible in the airway epithelia of immunocompetent mice without radical modification of Ad vector and in spite of the presence of CTLs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696826      PMCID: PMC109954     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression.

Authors:  A I Michou; L Santoro; M Christ; V Julliard; A Pavirani; M Mehtali
Journal:  Gene Ther       Date:  1997-05       Impact factor: 5.250

2.  Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector.

Authors:  Q Wang; G Greenburg; D Bunch; D Farson; M H Finer
Journal:  Gene Ther       Date:  1997-05       Impact factor: 5.250

3.  Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo.

Authors:  S C Wadsworth; H Zhou; A E Smith; J M Kaplan
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung.

Authors:  J M Kaplan; A E Smith
Journal:  Hum Gene Ther       Date:  1997-06-10       Impact factor: 5.695

5.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.

Authors:  N Morral; W O'Neal; H Zhou; C Langston; A Beaudet
Journal:  Hum Gene Ther       Date:  1997-07-01       Impact factor: 5.695

6.  Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway.

Authors:  A Scaria; J A St George; R J Gregory; R J Noelle; S C Wadsworth; A E Smith; J M Kaplan
Journal:  Gene Ther       Date:  1997-06       Impact factor: 5.250

7.  Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2.

Authors:  J M Kaplan; J A St George; S E Pennington; L D Keyes; R P Johnson; S C Wadsworth; A E Smith
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

8.  Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung.

Authors:  J M Kaplan; D Armentano; T E Sparer; S G Wynn; P A Peterson; S C Wadsworth; K K Couture; S E Pennington; J A St George; L R Gooding; A E Smith
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

9.  Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression.

Authors:  Y Ilan; G Droguett; N R Chowdhury; Y Li; K Sengupta; N R Thummala; A Davidson; J R Chowdhury; M S Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

10.  Increased contact time improves adenovirus-mediated CFTR gene transfer to nasal epithelium of CF mice.

Authors:  C Jiang; G Y Akita; W H Colledge; R A Ratcliff; M J Evans; K M Hehir; J A St George; S C Wadsworth; S H Cheng
Journal:  Hum Gene Ther       Date:  1997-04-10       Impact factor: 5.695

View more
  8 in total

1.  E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.

Authors:  D Armentano; M P Smith; C C Sookdeo; J Zabner; M A Perricone; J A St George; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes.

Authors:  J M Kaplan; D Armentano; A Scaria; L A Woodworth; S E Pennington; S C Wadsworth; A E Smith; R J Gregory
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect.

Authors:  G Wang; V Slepushkin; J Zabner; S Keshavjee; J C Johnston; S L Sauter; D J Jolly; T W Dubensky; B L Davidson; P B McCray
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

4.  Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.

Authors:  M Lusky; L Grave; A Dieterlé; D Dreyer; M Christ; C Ziller; P Furstenberger; J Kintz; D A Hadji; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

5.  A truncated CFTR protein rescues endogenous DeltaF508-CFTR and corrects chloride transport in mice.

Authors:  Estelle Cormet-Boyaka; Jeong S Hong; Bakhram K Berdiev; James A Fortenberry; Jessica Rennolds; J P Clancy; Dale J Benos; Prosper N Boyaka; Eric J Sorscher
Journal:  FASEB J       Date:  2009-07-20       Impact factor: 5.191

Review 6.  Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

Authors:  De-chu C Tang; Jianfeng Zhang; Haroldo Toro; Zhongkai Shi; Kent R Van Kampen
Journal:  Expert Rev Vaccines       Date:  2009-04       Impact factor: 5.217

Review 7.  Clinical review: gene-based therapies for ALI/ARDS: where are we now?

Authors:  James Devaney; Maya Contreras; John G Laffey
Journal:  Crit Care       Date:  2011-06-20       Impact factor: 9.097

Review 8.  Gene therapy for cystic fibrosis: an example for lung gene therapy.

Authors:  U Griesenbach; D M Geddes; E W F W Alton
Journal:  Gene Ther       Date:  2004-10       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.